Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study

Am J Hematol. 2022 Feb 1;97(2):E40-E44. doi: 10.1002/ajh.26404. Epub 2021 Dec 6.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Benzoates / adverse effects
  • Benzoates / therapeutic use*
  • Female
  • France / epidemiology
  • Humans
  • Hydrazines / adverse effects
  • Hydrazines / therapeutic use*
  • Male
  • Middle Aged
  • Off-Label Use
  • Prospective Studies
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Purpura, Thrombocytopenic, Idiopathic / epidemiology
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Treatment Outcome

Substances

  • Benzoates
  • Hydrazines
  • Pyrazoles
  • eltrombopag